Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Assessment of Prolonged Pain in Infants With Excessive Crying: Contribution of Infrared Thermal Imaging - The NEOTHERM Pilot Study (NEOTHERM)

maanantai 31. elokuuta 2026 päivittänyt: Centre Hospitalier de Saint-Denis
NEOTHERM is a multicenter, prospective, observational pilot study examining whether infrared thermal imaging (ITI) can contribute to the assessment of prolonged pain in infants with excessive crying. Thermal measurements of the face and body will be compared with scores obtained using the EDIN behavioral pain and discomfort scale. The study will also examine associations between ITI measures, EDIN scores, and hair cortisol concentrations as a biomarker of prolonged stress, and will describe early motor organization and psychomotor development using General Movements Assessment and Bayley-4. Eighty infants will be enrolled in two comparison groups based on daily crying duration and assessed longitudinally at two standardized visits. The main hypothesis is that ITI will identify cutaneous thermal changes associated with prolonged pain and that these measures will be associated with EDIN scores.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

80

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

    • Île-de-France Region
      • Paris, Île-de-France Region, Ranska, 75003
        • Centre Médico-Psychologique Périnatalité et Petite Enfance Brantôme
        • Ottaa yhteyttä:
      • Saint-Denis, Île-de-France Region, Ranska, 93200
        • Centre Hospitalier de Saint-Denis - Department of Neonatology
        • Ottaa yhteyttä:
      • Saint-Denis, Île-de-France Region, Ranska, 93200
        • Centre Hospitalier de Saint-Denis - Department of Perinatal Psychiatry
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Lapsi

Hyväksyy terveitä vapaaehtoisia

Joo

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

Experimental group: excessive crying duration

The study population will comprise 80 infants recruited prospectively from three participating centers. Infants will be enrolled at 2 to 6 weeks post-term in corrected age and reassessed at 10 to 14 weeks post-term in corrected age.

Based on the 7-day parental crying diary completed before the first assessment, infants will be classified into two predefined cohorts: an excessive-crying (EC) cohort and a typical-crying (TC) cohort, with 40 infants planned in each cohort.

Participants in the TC cohort will be matched to participants in the EC cohort according to corrected age at assessment (±1 week), sex when possible, gestational age at birth (±1 week), feeding modality, and maternal parity.

Kuvaus

Inclusion criteria:

  • Infants aged 2 to 6 weeks post-term in corrected age at the first assessment.
  • Born at or after 32 weeks' gestational age.
  • No known neurological or gastrointestinal disease.
  • Written informed consent from the holder(s) of parental authority.
  • Meeting the criteria for one of the following two cohorts:

    • Excessive-crying (EC) cohort: crying for more than 3 hours per day on at least 3 consecutive days during the 7 days preceding the assessment (modified Wessel criteria), together with at least two of the following three protocol-specified Rome IV-related features: crying without an apparent cause, inconsolable crying, and associated signs including agitation, facial flushing, clenched fists, and/or flexed legs.
    • Typical-crying (TC) cohort: crying for less than 2 hours per day during the week preceding the assessment.

Infants crying for 2 to 3 hours per day during the week preceding the assessment will not be included in either cohort.

Exclusion criteria:

  • Confirmed cerebral lesions identified by ultrasound or magnetic resonance imaging.
  • Major congenital or chromosomal abnormalities.
  • Growth faltering.
  • Birth before 32 weeks' gestational age.
  • Holder(s) of parental authority who do not speak French.
  • Lack of written informed consent from the holder(s) of parental authority.
  • Lack of affiliation with a French social security scheme.
  • Any situation falling under specific legal protection provisions under French law.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

Kohortit ja interventiot

Ryhmä/Kohortti
Excessive-Crying (EC) Cohort

Infants aged 2 to 6 weeks post-term (corrected age) at the first assessment, with crying lasting more than 3 hours per day on at least 3 consecutive days during the 7 days preceding the assessment (modified Wessel criteria). Infants must also meet at least two of the following three protocol-specified Rome IV-related features: crying without an apparent cause, inconsolable crying, and associated signs including agitation, facial flushing, clenched fists, and/or flexed legs.

No intervention will be assigned. Participants will undergo the observational assessments specified in the study protocol.

Typical-Crying (TC) Cohort

Infants aged 2 to 6 weeks post-term (corrected age) at the first assessment, with crying lasting less than 2 hours per day during the 7 days preceding the assessment.

Participants in the TC cohort will be matched to participants in the EC cohort according to corrected age at assessment (±1 week), sex where possible, gestational age at birth (±1 week), feeding modality, and maternal parity.

No intervention will be assigned. Participants will undergo the observational assessments specified in the study protocol.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Association Between Infrared Thermal Imaging Indices and EDIN Total Score
Aikaikkuna: At baseline (T1) and approximately 8 weeks after baseline (T2)

Mean skin temperatures will be extracted from predefined body and facial regions of interest. Infrared thermal imaging indices will include absolute bilateral body temperature differences, central-to-peripheral temperature gradients, and intra-facial temperature gradients calculated relative to the forehead. An absolute temperature difference greater than 0.5°C will be considered an abnormal thermal asymmetry.

The EDIN is a behavioral scale assessing facial expression, body movements, sleep, interaction, and consolability. Each item is scored from 0 to 3. Higher scores indicate greater pain- or discomfort-related behaviors; a total score of 5 or higher indicates probable prolonged pain.

Concordance between infrared thermal imaging indices and EDIN total scores will be quantified using Spearman rank correlation coefficients at each assessment. Thermal images will be analyzed by an external assessor blinded to the EDIN score and cohort classification.

At baseline (T1) and approximately 8 weeks after baseline (T2)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Associations Between Hair Cortisol Concentration, Infrared Thermal Imaging Indices, and EDIN Total Score
Aikaikkuna: At baseline (T1) and approximately 8 weeks after baseline (T2)

Hair cortisol concentration will be measured in pg/mg of hair from a small sample collected from the occipital region. Cortisol will be quantified using high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS).

Hair cortisol concentration will be investigated as a biomarker of prolonged stress. Spearman correlation coefficients will be calculated between hair cortisol concentration, infrared thermal imaging indices, and EDIN total scores

At baseline (T1) and approximately 8 weeks after baseline (T2)
General Movements Assessment Scores and Motor Patterns
Aikaikkuna: At baseline (T1); approximately 15, 30, and 45 days after baseline; and approximately 8 weeks after baseline (T2)

Spontaneous general movements will be recorded with the infant lying supine, wearing only a diaper or onesie, during 2 to 5 minutes of active wakefulness without crying, interaction, a pacifier, or hiccups. Recordings will be independently evaluated by two assessors trained in General Movements Assessment and blinded to cohort classification, EDIN scores, and infrared thermal imaging results.

The General Movement Optimality Score-Revised (GMOS-R; maximum score 38) will be used at Visit 1. The Motor Optimality Score- Revised (MOS-R) will be used at Visit 2; scores of 25 to 28 are considered optimal, whereas lower scores indicate less optimal motor organization. Qualitative motor characteristics, including movement quality, variability, fluency, symmetry, posture, and atypical movement patterns, will also be described and compared between cohorts.

At baseline (T1); approximately 15, 30, and 45 days after baseline; and approximately 8 weeks after baseline (T2)
Psychomotor Development Assessed Using the Bayley Scales of Infant and Toddler Development, Fourth Edition
Aikaikkuna: At baseline (T1) and approximately 8 weeks after baseline (T2)

Psychomotor development will be assessed using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4). Five subtests will be administered: cognitive development, receptive communication, expressive communication, fine motor development, and gross motor development.

Raw subtest scores will be converted to scalar and composite scores using the normative tables of the Bayley-4. Higher scores indicate better performance in the assessed developmental domain. Scores will be compared between the EC and TC cohorts. Scoring will be performed by an assessor blinded to cohort classification.

At baseline (T1) and approximately 8 weeks after baseline (T2)
Associations Between Early Motor Organization and Prolonged Pain or Stress Indicators
Aikaikkuna: From baseline (T1) through approximately 8 weeks after baseline (T2)
Associations between General Movements characteristics, GMOS-R or MOS scores, Bayley-4 scores, infrared thermal imaging indices, EDIN total scores, and hair cortisol concentrations will be examined using Spearman correlations and exploratory regression analyses.
From baseline (T1) through approximately 8 weeks after baseline (T2)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Tiistai 1. syyskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Lauantai 1. heinäkuuta 2028

Opintojen valmistuminen (Arvioitu)

Lauantai 1. heinäkuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 17. kesäkuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 3. heinäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 9. heinäkuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 3. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 31. elokuuta 2026

Viimeksi vahvistettu

Lauantai 1. elokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa